Novo Nordisk Paid $700M for a Drug. Now It Wants the Money Back.

But instead of quietly licking its wounds, Novo went on the offensive. The company filed for New York-seated ICC arbitration and obtained a supportive freezing order from the Singapore International Commercial Court, alleging something far more serious than a drug that simply didn't pan out.

The Fraud Allegations

Novo's accusation boils down to this: KBP knew the drug was unlikely to work and sold it anyway.

According to Novo, KBP had interim Phase 2 data from 2022 showing ocedurenone probably wouldn't demonstrate efficacy. KBP allegedly buried that data.

The Singapore court apparently found Novo's case compelling enough to grant a worldwide asset freeze on KBP and its founder, Dr. Zhenhua Huang, who owns roughly 40% of the company. The freeze covers up to $730 million per respondent. The court noted that KBP had transferred $339 million and paid $578 million in dividends after the deal closed, which (to put it diplomatically) raised some eyebrows about whether assets were being moved out of reach.

KBP Fires Back

KBP isn't taking the allegations lying down. The company's defense is essentially: "You had the receipts. You just didn't read them."

According to KBP, Novo Nordisk had access to a full electronic data room during due diligence. That room contained Phase 2 vital signs data, systolic blood pressure readings, and other raw files. KBP says Novo never opened or analyzed key documents, including a Vital Signs Data Listing and a CTA Package. Think of it like buying a used car without ever popping the hood, then complaining about the engine.

KBP also disputes the trial's futility conclusion itself. After the monitoring committee stopped the study, KBP argues that once data errors were corrected, the data met only one of the futility criteria instead of both. KBP argues the drug actually showed a "significant but not substantial" effect and that the trial was worth continuing.

That's a remarkable claim: not just "we didn't commit fraud," but "you killed a drug that was still working."

Independent Voices Weigh In

The dispute got even more interesting in December 2024, when two members of the Phase 3 trial's steering committee published an open letter. Dr. Bertram Pitt and Dr. Janet Wittes stated there was no convincing evidence of fraud.

That's a notable signal. When senior clinical researchers publicly defend a trial's integrity during active litigation, they're putting their professional reputations on the line.

Why This Matters Beyond Two Companies

Licensing deals are the backbone of the biotech industry. Small companies discover drugs; big companies pay to develop and sell them. The whole system runs on trust: trust that the data is real, trust that the due diligence is thorough, trust that both sides are acting in good faith.

This dispute is a stress test for that trust. If Novo's allegations prove true, it sends a chilling message about the risks of acquiring early-stage assets. If KBP's defense holds, it raises uncomfortable questions about how carefully pharma giants actually scrutinize the deals they're signing. Either outcome creates new anxiety in boardrooms on both sides of the table.

The legal fight is far from over. Novo Nordisk has initiated New York-seated arbitration, and the Singapore injunction was upheld as of August 2025. A full tribunal review with live testimony is still pending.

The Bottom Line

Novo Nordisk wrote a $700 million check for a drug it believed could help millions of patients with uncontrolled hypertension and kidney disease. Less than a year later, the trial collapsed, and now the two companies are in an all-out legal brawl over who's to blame.

KBP says Novo didn't do its homework. Novo says KBP hid the answers. $830 million and two corporate reputations hang in the balance. In an industry built on billion-dollar handshakes, this case could rewrite the rules of how those deals get done.

From $100M IPO to Liquidation in Five Years

IO Biotech went from a $100M IPO and "most innovative biotech" honors to total Chapter 7 liquidation in five years, all because its cancer vaccine trial missed statistical significance by the thinnest of margins. It's the most brutal cautionary tale in immuno-oncology right now.